March 15, 2022.
Dear all,Company name:
SUNCORPORATIONName of representative: Ryusuke Utsumi,
CEO(Code No. 6736 TSE JASDAQ)
For further information, please contact
Yoshimi Kimura, Senior Managing Director(Tel 052-756-5981)

Notice on the forecast results and dividends for the fiscal year ending in March 2022

Please be advised that SUNCORPORATION has decided to make the following changes to its undisclosed
full-year forecasts and dividend forecasts for the year ending March 31, 2022.
１． Performance forecast(1) Reasons for the forecast
Based on recent economic trends and the financial results of overseas subsidiaries and other entities,
SUNCORPORATION is announcing the following consolidated forecasts for the fiscal year ending in March
2022, which have not yet been announced.
(2) Forecast consolidated results for the fiscal year ending in March 2022 (April 1, 2021 - March 31, 2022)(million yen)

Period.

Sales

Operatingprofits

Ordinary
profits

Net profit for theyear attributable
to the parentcompany

Net profit for
the year pershare

Forecasts for this time

37,50038,000

1,400-1,500

7,500-.
8,000

2,300-.
2,40092.00 -.
98.00 yen

(Reference) Previousyear's results(Fiscal year ended inMarch 31, 2021)

26,662

687

881

47

2.08 yen

Increase/decrease
from the previous year
(%)

41-43

104-118751-808－－

As announced today in the "Notice on non-operating income", regarding the derivative liabilities recordedin connection with the merger agreement entered into when Cellebrite DI Ltd (“Cellebrite”), a consolidated
subsidiary of SUNCORPORATION, became listed on NASDAQ on August 30, 2021, a gain on valuation ofderivatives arising from changes in fair value due to changes in Cellebrite's share price and other factors will
be recorded as non-operating income. These liabilities affect the Group's results and financial position due tochanges in the fair value of Cellebrite's share price and other factors. Therefore, depending on the pricemovement of Cellebirte's share price in the following term, SUNCORPORATION may record a loss on
valuation of derivatives as a non-operating expense due to an increase in the fair value of the liabilities.

As a side note, the book closing date of the foreign subsidiaries, including Cellebrite, is December 31, 2021.
When forecasting the consolidated financial results, we use the financial statements as of the same date,
December 31, 2021. As for the material discrepancies in accounting records related to the transactions between
consolidated companies, which arise from the book closing date difference, we make the necessary adjustments
to consolidate the figures.
２． Dividend forecast
Annual dividend (yen)End of second quarterend of term

total amountPrevious
forecast

undecided

undecided

Revisedforecast

20.00

40.00

10.00

10.00

Actual results
for this term20.00

Results of theprevious year

0.00

The Company's basic policy is to actively and flexibly distribute profits according to the performance, taking
into account the medium- and long-term free cash flow and the dividend payout ratio, in order to develop thebusiness for the future, strengthen the management base and increase corporate value over the medium term.
As a result of the solid performance of the current financial year and taking into account the financial positionof the company, the year-end dividend forecast for the current financial year has been set at 20 yen per share.